The Combination of D-TACE-HAIC, Lenvatinib, and PD-1 Inhibitors Shows Significant Clinical Efficacy in Patients with Unresectable Hepatocellular Carcinoma
In summary, D-TACE-HAIC + lenvatinib + PD-1 inhibitor treatment exhibits a favorable safety profile, outperforming TACE + sorafenib treatment for unresectable HCC patients while improving overall rates of translational efficacy, increasing rates of surgical conversion, prolonging patient survival, and conferring long-term survival benefits.
Authors
- Yintao Wu
- Nian-Xin Xia (ORCID: https://orcid.org/0009-0007-7841-6806)
- Hong Zhang (ORCID: https://orcid.org/0000-0001-9445-4932)
- Jianyong Zhu
Institutions
- Chinese PLA General Hospital (CN)
Publication Details
- Journal
- Cancer Management and Research
- Published
- 2025-02-01
- DOI
- https://doi.org/10.2147/cmar.s481242
- Citations
- 4
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 5.29